Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Acquires $88,875.84 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt purchased 25,836 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was bought at an average price of $3.44 per share, for a total transaction of $88,875.84. Following the acquisition, the insider owned 71,842 shares of the company’s stock, valued at $247,136.48. This represents a 56.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 1st, Financial Lp Hrt acquired 3,959 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.23 per share, with a total value of $21,818.65.

Shuttle Pharmaceuticals Trading Up 2.0%

NASDAQ:SHPH opened at $3.65 on Friday. The company has a 50-day moving average price of $5.69 and a 200-day moving average price of $10.59. The stock has a market cap of $2.34 million, a price-to-earnings ratio of -0.08 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a 12 month low of $2.90 and a 12 month high of $55.90.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Institutional Trading of Shuttle Pharmaceuticals

A number of hedge funds have recently modified their holdings of SHPH. Geode Capital Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter worth about $26,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals during the 4th quarter valued at about $37,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals during the 4th quarter valued at about $124,000. Finally, Connective Capital Management LLC purchased a new position in Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. Institutional investors own 4.58% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Weiss Ratings raised Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .